Skip to main content

Dr. Sager joins after 18 months as part-time CMO, in which he built the clinical program for Angiex’s lead drug AGX101. Dr Sager brings valuable oncology patient care and clinical development experience to the company in its transition to a clinical stage company.

CAMBRIDGE, Mass. — October 1, 2022: Angiex, developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, has appointed Jason Sager, MD, as Chief Medical Officer (CMO).

Following a 12-year career as a practicing pediatric oncologist, Dr. Sager gained extensive oncology drug development experience at Genentech, Novartis, Sanofi and Ikena Oncology where he led the early clinical development of many important therapeutics. His résumé includes 14 INDs. Over the past 18 months, he led the design of the clinical program for Angiex’s lead drug, AGX101.

Angiex CEO, Marty J. Duvall said, “The addition of Jason to our executive team is a critical step in the growth of our company. His extensive know-how and drug development network will help accelerate our company forward.”

”I am highly motivated to join Angiex. The company has a deep scientific foundation in angiogenesis, vascular biology, and antibody-drug conjugate chemistry. I am driven to translate that into a meaningful benefit for cancer patients,” said Dr. Sager.

Iain Dukes, executive chairman of Angiex and venture partner of Orbimed Advisors, said, “Adding Jason to the executive team marks another important milestone in the building of Angiex. Angiex’s ND-ADC technology holds great promise for the treatment of solid cancers and deserves a world-class team to drive it forward.”

About Angiex 

Angiex Inc. is a privately held biotech startup whose mission is to exploit newly discovered biological transport mechanisms to make drugs with revolutionary power over cancer. Based in Cambridge, Mass., Angiex was founded by a scientific team of leading experts in angiogenesis, vascular biology, and oncology. The company is developing a novel portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) that release therapeutic payloads directly into the nucleus or cytosol, where the site of payload action is located. This direct delivery holds the promise of enhancing the efficacy and therapeutic margin of conventional ADCs. The lead product, AGX101, has advanced through pre-clinical development and is about to begin Phase 1 clinical trials. To learn more about Angiex, visit angiex.com.